3 Stocks Advancing The Health Care Sector
All three major indices are trading up today with the
Dow Jones Industrial Average
(
^DJI
) trading up 137 points (0.7%) at 18,509 as of Thursday, July 14, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,870 issues advancing vs. 1,053 declining with 127 unchanged.
The Health Care sector currently sits down 0.2% versus the S&P 500, which is up 0.5%. Top gainers within the sector include
Valeant Pharmaceuticals International
(
), up 3.4%,
(
), up 1.9%,
(
), up 1.7%,
(
), up 1.3% and
(
), up 1.1%. A company within the sector that fell today was
(
), up 1.4%.
TheStreet would like to highlight 3 stocks pushing the sector higher today:
3.
(
) is one of the companies pushing the Health Care sector higher today. As of noon trading, Express Scripts is up $0.90 (1.1%) to $79.50 on light volume. Thus far, 1.3 million shares of Express Scripts exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $78.88-$80.02 after having opened the day at $78.94 as compared to the previous trading day's close of $78.60.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States, Canada, and Europe. The company operates through two segments, PBM and Other Business Operations. Express Scripts has a market cap of $49.5 billion and is part of the health services industry. Shares are down 10.1% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Express Scripts a buy, 2 analysts rate it a sell, and 8 rate it a hold.
TheStreet Ratings rates
Express Scripts
as a
. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, notable return on equity, good cash flow from operations and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
Express Scripts Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is up $0.68 (0.9%) to $80.04 on average volume. Thus far, 1.7 million shares of Eli Lilly and exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $79.40-$80.40 after having opened the day at $79.50 as compared to the previous trading day's close of $79.36.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and has a market cap of $87.9 billion and is part of the drugs industry. Shares are down 5.8% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Eli Lilly and
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $0.33 (0.9%) to $36.64 on average volume. Thus far, 12.3 million shares of Pfizer exchanged hands as compared to its average daily volume of 27.1 million shares. The stock has ranged in price between $36.25-$36.83 after having opened the day at $36.49 as compared to the previous trading day's close of $36.31.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $219.8 billion and is part of the drugs industry. Shares are up 12.5% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Pfizer a buy, no analysts rate it a sell, and 6 rate it a hold.
TheStreet Ratings rates
Pfizer
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider
Health Care Select Sector SPDR
(
) while those bearish on the health care sector could consider
ProShares Ultra Short Health Care
(
).